Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.68 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | CHKA | P35790 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014151 | 0.90 | EGFR (0.59) | CSF1REGFRPDGFRBKDRCHKA | |
| SCHEMBL23577274 | 0.90 | EGFR (0.59) | CSF1REGFRPDGFRBKDRCHKA | |
| SCHEMBL30014088 | 0.87 | MAPT (0.56) | CSF1REGFRPDGFRBKDRMAPT | |
| SCHEMBL23577073 | 0.87 | MAPT (0.56) | CSF1REGFRPDGFRBKDRMAPT | |
| SCHEMBL23601088 | 0.85 | EGFR (0.54) | CSF1REGFRPDGFRBKDRMAPT | |
| SCHEMBL30961012 | 0.85 | EGFR (0.54) | CSF1REGFRPDGFRBKDRMAPT | |
| SCHEMBL23577990 | 0.85 | EGFR (0.54) | CSF1REGFRPDGFRBKDRMAPT | |
| SCHEMBL30961085 | 0.85 | EGFR (0.54) | CSF1REGFRPDGFRBKDRMAPT | |
| SCHEMBL3114872 | 0.85 | EGFR (0.72) | CSF1REGFRPDGFRBKDR | |
| SCHEMBL3110618 | 0.84 | EGFR (0.76) | EGFRPDGFRBKDRMAPTPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| CN-117736207-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-115362003-B | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CSF1R 2614/4885EGFR 1239/4885PDGFRB 1157/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CSF1R 2614/4885EGFR 1239/4885PDGFRB 1157/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | CSF1R 2614/4885EGFR 1239/4885PDGFRB 1157/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | CSF1R 2614/4885EGFR 1239/4885PDGFRB 1157/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CSF1R 2614/4885EGFR 1239/4885PDGFRB 1157/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CSF1R 2614/4885EGFR 1239/4885PDGFRB 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.